This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on prevention and treatment—if they keep current with developments in drug therapy.
Get full access to this article
View all access options for this article.
References
1.
ChobanianA.V., BakrisG.L., BlackH.R.. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA.2003; 289: 2560–2572.
2.
2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens.2003; 21: 1011–1053.
3.
National Collaborating Centre for Chronic Conditions.Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update.London, UK: Royal College of Physicians, 2006.
4.
WilhelmsenL., BerglundG., ElmfeldtD.. Beta Blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens.1987; 5: 561–572.
5.
Medical Research Council Working Party.MRC trial of treatment of mild hypertension: principal results. Br Med J.1985; 291: 97–104.
6.
MRC Working Party.Medical Research Council Trial of treatment of hypertension in older adults: principal results. Br Med J.1992; 304: 405–412.
7.
DahlofB., DevereuxR.B., KjeldsenS.E.. Cardiovascular morbidity and mortality in the losartan intervention for end point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet.2002; 359: 995–1003.
8.
WachtellK., LehtoM., GerdtsE.. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol.2005; 45: 712–719.
9.
LindholmL.H., IbsenH., Borch-JohnsenK.. Risk of new-onset diabetes in the Losartan Intervention For End point reduction in hypertension study. J Hypertens.2002; 20: 1879–1886.
10.
LindholmL.H., IbsenH., DahlofB.. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet.2002; 359: 1004–1010.
11.
DahlofB., SeverP.S., PoulterN.R.. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomized controlled trial. Lancet.2005; 366: 895–906.
12.
ZanchettiA., BondM.G., HennigM.. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation.2002; 106: 2422–2732.
13.
PepineC.J., HandbergE.M., Cooper-DeHoffR.M.A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA.2003; 290: 2805–2816.
14.
Cooper-DehoffR., CohenJ.D., BakrisG.L.. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (Findings from INternational VErapamil SR-Trandolapril STudy (INVEST). Am J Cardiol.2006; 98: 890–894.
15.
LindholmL.H., CarlbergB., SamuelssonO.Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet.2005; 366: 1545–1553.
16.
CollinsR., PetoR., MacMahonS.. Blood pressure, stroke and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet.1990; 335: 827–838.
17.
KhanN., McAlisterF.A.Beta blockers for the treatment of primary hypertension (Letter). Lancet.2006; 367: 208.
18.
CruickshankJ.M.Beta blockers for the treatment of primary hypertension (Letter). Lancet.2006; 367: 209.
19.
FranklinS.S., GustinW., WondN.D.. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation.1997; 96: 308–315.
20.
ResnickL.M., LesterM.H.Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens.2002; 15: 1096–1100.
21.
KhanN., McAllisterF.A.Re-examining the efficacy of beta blockers for the treatment of hypertension: a meta-analysis. CMAJ.2006; 174: 1737–1742.
22.
Medical Research Council Working Party.Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Br Med J.1988; 296: 1565–1570.
23.
BrewsterL.M., van MontfransG.A., KleijnenJ.Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med.2004; 141: 614–627.
24.
BeeversD.G.The end of beta-blockers for uncomplicated hypertension?Lancet.2005; 366: 1510–1512.
25.
FrishmanW.H.Beta-adrenergic blocker withdrawal. Am J Cardiol.1987; 59: 26F–32F.
26.
The National Heart, Lung, and Blood Institute Working Group on Future Directions in Hypertension Treatment Trials.Major clinical trials of hypertension: what should be done next?Hypertension.2005; 46: 1–6.
